Inhaled mannitol for the treatment of cystic fibrosis

Expert Review of Respiratory Medicine

Volumn 6, Issue 1, 2012, Pages 19-26

  Hurt, Katharine ^a   Bilton, Diana ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Cystic fibrosis; Hyperosmolar; Inhaled therapy; Mannitol; Mucociliary clearance; Mucolytic hypertonic saline; rhDNase

Indexed keywords

DENOFUSOL; DORNASE ALFA; MANNITOL; MUCOLYTIC AGENT; PLACEBO; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

AIRWAY; BIOAVAILABILITY; BRONCHIECTASIS; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRY POWDER; FORCED EXPIRATORY VOLUME; HUMAN; HYDRATION; LUNG DISEASE; MUCOCILIARY CLEARANCE; NONHUMAN; PATHOPHYSIOLOGY; POWDER INHALER; REVIEW; WATER FLOW;

EID: 84856491914     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.11.87     Document Type: Review

References (49)

1. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N. Engl. J. Med. 335(3), 179-188 (1996). (Pubitemid 26249456)
2. Dodge JA, Morison S, Lewis PA et al. Incidence, population, and survival of cystic fibrosis in the UK, 1968-1995. Arch. Dis. Child. 77(6), 493-496 (1997). (Pubitemid 28016366)
3. The Cystic Fibrosis Trust's Clinical Standards and Accreditation Group. Standards for the clinical care of children and adults with cystic fibrosis in the UK 2001. CF Trust 1-56 (2001).
4. Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J. Intern. Med. 261(1), 5-16 (2007). (Pubitemid 46046468)
5. Rowe SM, Miller S, Sorscher EJ. Cystic Fibrosis. N. Engl. J. Med. 352(19), 1992-2001 (2005). (Pubitemid 40638370)
6. Donaldson SH, Boucher RC. Update on pathogenesis of cystic fibrosis lung disease. Curr. Opin. Pulm. Med. 9(6), 486-491 (2003). (Pubitemid 37268212)
7. Frizzell RA, Pilewski JM. Finally, mice with CF lung disease. Nat. Med. 10(5), 452-454 (2004). (Pubitemid 38667896)
8. Mall M, Grubb BR, Harkema JR, O'Neal WK, Boucher RC. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat. Med. 10(5), 487-493 (2004). (Pubitemid 38667907)
9. Ratjen F, Doring G. Cystic fibrosis. Lancet 361(9358), 681-689 (2003). (Pubitemid 36246556)
10. Cohen AB, Gold WM. Defense mechanisms of the lungs. Annu. Rev. Physiol. 37(1), 325-350 (1975).
11. Shah PL, Scott SF, Knight RA, Marriott C, Ranasinha C, Hodson ME. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax 51(2), 119-125 (1996). (Pubitemid 26060647)
12. Fuchs HJ, Borowitz DS, Christiansen DH et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N. Engl. J. Med. 331(10), 637-642 (1994). (Pubitemid 24276863)
13. Quan JM, Tiddens HAWM, Sy JP et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J. Pediatr. 139(6), 813-820 (2001). (Pubitemid 34014460)
14. Mccoy K, Hamilton S, Johnson C. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest 110(4), 889-895 (1996). (Pubitemid 26347599)
15. Konstan MW, Wagener JS, Pasta DJ et al.; for the Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Clinical use of dornase alfa is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatr. Pulmonol. 46(6), 545-553 (2011).
16. George PM, Banya W, Pareek N et al. Improved survival at low lung function in cystic fibrosis: Cohort study from 1990 to 2007. BMJ 342, d1008 (2011).
17. Jones AP, Wallis C. Dornase alfa for cystic fibrosis. Cochrane Database Syst. Rev. 17(3), CD001127 (2010).
18. Heijerman H, Westerman E, Conway S, Touw D. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. J. Cyst. Fibros. 8(5), 295-315 (2009).
19. Scheffner AL, Medler EM, Jacobs LW, Sarett HP. The in vitro reduction in viscocity of human tracheobronchial secretions by acetylcysteine. Am. Rev. Respir. Dis. 90, 721-729 (1964).
20. Nash EF, Stephenson A, Atjen F, Tullis E. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst. Rev. 21(1), CD007168 (2009).
21. Elkins MR, Robinson M, Rose BR et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N. Engl. J. Med. 354(3), 229-240 (2006). (Pubitemid 43113028)
22. Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst. Rev. 2, CD001506 (2009).
23. Gustafsson PM, Aurora P, Lindblad A. Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis. Eur. Respir. J. 22(6), 972-979 (2003). (Pubitemid 37540651)
24. Gustafsson PM, De Jong PA, Tiddens HAWM, Lindblad A. Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. Thorax 63(2), 129-134 (2008). (Pubitemid 351236476)
25. Accurso FJ, Moss RB, Wilmott RW et al. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am. J. Respir. Crit. Care Med. 183(5), 627-634 (2011).
26. Joint Formulary Committee. British National Formulary 60. Joint Formulary Committee (Ed.). BMJ Group and Pharmaceutical Press, London, UK (2010).
27. Anderson S, Charlton B, Weiler J et al. Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma. Respir. Res. 10(1), 4 (2009).
28. Brannan J, Anderson S, Perry C et al. The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: A Phase 3 comparison study with hypertonic (4.5%) saline. Respir. Res. 6(1), 144 (2005).
29. Bilton D, Robinson P, Cooper P et al. Inhaled dry powder mannitol in cystic fibrosis: An efficacy and safety study. Eur. Respir. J. 38(5), 1071-1080 (2011).
30. Investigator's Brochure: Bronchitol (inhaled dry powder mannitol for airway disease). Pharmaxis (10), section 4-6 (2010).
31. Verdugo P. Goblet cells secretion and mucogenesis. Annu. Rev. Physiol. 52(1), 157-176 (1990). (Pubitemid 20103532)
32. King M, Rubin B. Pharmacological approaches to discovery and development of new mucolytic agents. Adv. Drug Deliv. Rev. 54(11), 1475-1490 (2002). (Pubitemid 35375771)
33. Wills PJ, Hall RL, Chan W, Cole PJ. Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucusdepleted bovine trachea. J. Clin. Invest. 99(1), 9-13 (1997). (Pubitemid 27058287)
34. Brannan JD, Gulliksson M, Anderson SD, Chew N, Kumlin M. Evidence of mast cell activation and leukotriene release after mannitol inhalation. Eur. Respir. J. 22(3), 491-496 (2003). (Pubitemid 37098931)
35. Robinson M, Daviskas E, Eberl S et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: A pilot study. Eur. Respir. J. 14(3), 678-685 (1999). (Pubitemid 29479736)
36. Daviskas E, Anderson SD, Brannan JD, Chan HK, Eberl S, Bautovich G. Inhalation of dry-powder mannitol increases mucociliary clearance. Eur. Respir. J. 10(11), 2449-2454 (1997). (Pubitemid 28048614)
37. Daviskas E, Anderson S, Eberl S, Chan HK, Bautovich G. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. 159(6), 1843-1848 (1999). (Pubitemid 29275053)
38. Daviskas E, Anderson SD, Eberl S, Chan HK, Young IH. The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest 119(2), 414-421 (2001). (Pubitemid 32163751)
39. Daviskas E, Anderson SD, Young IH. Effect of mannitol and repetitive coughing on the sputum properties in bronchiectasis. Respir. Med. 104(3), 371-377 (2010).
40. Daviskas E, Anderson SD, Eberl S, Young IH. Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur. Respir. J. 31(4), 765-772 (2008).
41. Daviskas E, Anderson SD, Gomes K et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: Effect on lung function, health status and sputum. Respirology 10(1), 46-56 (2005). (Pubitemid 40343762)
42. Bilton D, Daviskas E, Jaques A, Anderson S, Charlton B. A randomised, placebocontrolled trial of inhaled mannitol in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. 179, A3221 (2009).
43. Jaques A, Daviskas E, Turton JA et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 133(6), 1388-1396 (2008). (Pubitemid 351892995)
44. Daviskas E, Anderson SD, Jaques A, Charlton B. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. Chest 137(4), 861-868 (2010).
45. Minasian C, Wallis C, Metcalfe C, Bush A. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: A randomised trial. Thorax 65(1), 51-56 (2010).
46. Minasian C, Wallis C, Metcalfe C, Bush A. Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis. Pediatr. Pulmonol. 43(11), 1078-1084 (2008).
47. Teper A, Jaques A, Charlton B. Inhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial. J. Cyst. Fibros. 10(1), 1-8 (2011).
48. Joint FAO/WHO Expert Committee on Food Additives. 616. Mannitol. WHO Food Additives Series 21 (1986).
49. Bartholdson SJ, Brown AR, Mewburn BR et al. Plant host and sugar alcohol induced exopolysaccharide biosynthesis in the Burkholderia cepacia complex. Microbiology 154(8), 2513-2521 (2008).